COVID-19 mRNA vaccines are highly efficacious in preventing COVID-19 morbidity and
mortality in phase 3 clinical studies as well as in real-world settings. Emerging evidence …

B-cell maturation antigen (BCMA) is a prominent tumor-associated target for chimeric antigen
receptor (CAR)-T cell therapy in multiple myeloma (MM). Here, we describe the case of a …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have been proven
to be highly effective at preventing severe disease and mortality in healthy individuals; …

B-cell maturation antigen (BCMA)–directed chimeric antigen receptor T-cell (CAR T) therapy
has demonstrated remarkable efficacy in patients with relapsed/refractory multiple myeloma…

Despite the efficacy of COVID-19 vaccines in healthy individuals, multiple myeloma (MM)
patients are immunocompromised and mount suboptimal humoral and cellular responses after …

The Pediatric Cardiac Genomics Consortium (PCGC) designed the Congenital Heart Disease
Genetic Network Study to provide phenotype and genotype data for a large congenital …

The remarkable genetic heterogeneity of multiple myeloma poses a substantial challenge
for proper prognostication and clinical management of patients. Here, we introduce MM-PSN, …

T-cell redirection therapy using chimeric antigen receptor (CAR) T cells and bispecific
antibodies (BiAbs) has shown promising efficacy in heavily pretreated patients with relapsed/…

Introduction: Chimeric antigen receptor T-cell therapy (CAR-T) directed against B-cell
maturation antigen (BCMA) is a highly effective treatment for patients with relapsed/refractory …

Chimeric antigen receptor T cell (CAR-T) therapy has demonstrated unprecedented clinical
efficacy, leading to global approvals of anti-CD19 CAR-T cells for the treatment of relapsed B …